Kappa opioid receptors (KORs) in the central nervous system have been known to be important regulators of a variety of psychiatry illnesses, including anxiety and addiction, but their precise involvement in these disorders is complex and has yet to be fully elucidated. Here, we briefly review the pharmacology of KORs in the brain, including KOR's involvement in anxiety, depression, and drug addiction. We also review the known neuronal circuitry impacted by KOR signaling, and interactions with corticotrophin-releasing factor (CRF), another key peptide in anxiety-related illnesses, as well as the role of glucocorticoids. We suggest that KORs are a promising therapeutic target for a host of neuropsychiatric conditions.
Introduction: KORs in the central nervous system
Kappa opioid receptors (KORs) and their endogenous ligand, the peptide dynorphin (Chavkin and Goldstein, 1981a,1981b; Chavkin et al., 1982) are at the forefront of potential therapeutic targets for a range of health issues, including anxiety, depression, and drug addiction (Bruchas et al., 2010) . Here, we outline current neurobiological research of KORs, focusing on the discrete circuit elements that are regulated by KOR signaling and their role in behavior.
Pharmacology
Kappa opioid receptors are seven transmembrane g-protein coupled receptors (GPCRs), coupled to Gαi/o, and are known to utilize a variety of signaling cascades (reviewed in detail, Bruchas and Chavkin, 2010) . KORs signal through both Gα and Gβγ subunits, and then activate a host of downstream signaling molecules, thereby activating g-protein gated inwardly rectifying potassium channels (GIRKs), reducing calcium currents, and decreasing cyclic AMP. KORs have been shown to activate both MEK/ERK (Belcheva et al., 2005; Hahn et al., 2010; Kivell et al., 2014a; Li, Pleil, et al., 2012; McLennan et al., 2008; Potter et al., 2011; Yoshizawa et al., 2011 ) (although some groups do not see significant MEK/ERK activation following KOR activation, see Asensio et al., 2006) and MAPK signaling cascades, and in particular, p38 (Bruchas et al., 2006 (Bruchas et al., , 2011 Hahn et al., 2010; Yoshizawa et al., 2011) . This KOR interaction with p38 is thought to be mediated by arrestin signaling; co-expression with the dominant-mutant form of β-arrestin prevents human KOR internalization in CHO cells (Li et al., 1999) . The interaction between p38 and arrestin may mediate the dysorphia-like side effects of KOR agonists (Bruchas et al., 2007) , possibly through a reduction in biogenic amine levels (Chefer et al., 2005; Spanagel et al., 1994 ) such as serotonin, as shown in Bruchas et al. The ability of KORs to signal through different GPCR signaling cascades may prove useful in creating biased agonists at the KOR, allowing for therapeutic treatments for pain or neuropsychiatric illnesses without the adverse side effects, such as dysphoria, and psychomemetic effects observed in humans (Pfeiffer et al., 1986) . Interestingly, KORs can utilize different signaling cascades in a single brain region (Hjelmstad and Fields, 2003) . Notably, Hjelmstad & Fields demonstrated that while KOR activation inhibits GABA release via a calcium dependent mechanism, it's inhibition of glutamate is calcium-independent. Other groups have similarly demonstrated KOR-mediated inhibition of GABA (Li, Pleil, et al., 2012) , but more in-depth assessments of biased KOR signaling in a single brain region have not been conducted. Potent long acting inhibitors of KOR include norBNI (Endoh et al., 1992) and JDTic (Bruchas and Chavkin, 2010 
